Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYP-011
- Development stage
- Unknown
- Lead developer
- Cynata Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CYP-011 is an investigational allogeneic cell therapy comprising mesenchymal stem cells (MSCs) derived from induced pluripotent stem cells (iPSCs) using the proprietary Cymerus™ manufacturing platform. Developed by Cynata Therapeutics, this product is designed to address the limitations of traditional MSC therapies, such as donor-to-donor variability and scalability issues, by utilizing a consistent iPSC source. The primary indication for CYP-011 is the prevention of organ rejection in patients undergoing renal transplantation. Its mechanism of action relies on the potent immunomodulatory properties of MSCs, which secrete a variety of cytokines and growth factors that suppress the activation and proliferation of T-lymphocytes and modulate the maturation of dendritic cells. By fostering a more tolerogenic immune environment, CYP-011 aims to improve long-term graft survival and potentially reduce the requirement for chronic, high-dose systemic immunosuppressive medications, which are associated with significant side effects.
- Other names
- Cymerus iPSC-MSCs
Beyond the preview
Go deeper on CYP-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYP-011.